AO-176, A Humanized Anti-CD47 Monoclonal Antibody that Directly Kills Human Tumor Cells and has Additional Unique Functional Characteristics

Robbyn Puro, Katherine Liu, Benjamin Capocia, Michael Donio, Ronald Hsieh, Myriam Bouchlaka, Allan Carter, Pamela Manning, Kathleen Crowley and Robert Karr

Arch Oncology, 4205 Forest Park Avenue, St. Louis, MO 63108 and 2000 Sierra Point Parkway, Brisbane, CA 94005

AO-176 Blocks the Binding of CD47 to SIRPα and Promotes Tumor Cell Phagocytosis

- **Introduction**
  - CD47 is a cell surface glycoprotein that interacts with signal regulatory protein alpha (SIRPα) on phagocytic cells and limits their phagocytic activity. This interaction is essential for protecting self-tissues from being phagocytosed by immune cells.

- **Results**
  - AO-176 is a humanized anti-CD47 monoclonal antibody that blocks the binding of CD47 to SIRPα, leading to enhanced phagocytosis of tumor cells.

- **Conclusion**
  - AO-176 is a promising therapeutic agent for the treatment of cancer, with potential for broad application in various cancer types.

**Acknowledgments**
- This study was supported by Arch Oncology. The authors thank Dr. C. Lin for editorial assistance.

**Poster 1765**